Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. The Company has a platform for discovering proprietary compounds that work through a modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.
|HQ||Evanston, IL, US||Map|
Net income (Q1, 2021)
EBIT (Q1, 2021)
Market capitalization (12-Nov-2021)
Closing stock price (12-Nov-2021)
|USD||Q2, 2018||Q3, 2018||Q1, 2019||Q2, 2019||Q3, 2019||Q1, 2020||Q2, 2020||Q1, 2021|
Depreciation and Amortization
Cash From Operating Activities
When was Aptinyx founded?
Aptinyx was founded in 2015.
Who are Aptinyx key executives?
Aptinyx's key executives are Patrick Enright, Juan Estupinan and Henry O. Gosebruch.
How many employees does Aptinyx have?
Aptinyx has 63 employees.
What is Aptinyx revenue?
Latest Aptinyx annual revenue is $1.6 m.
What is Aptinyx revenue per employee?
Latest Aptinyx revenue per employee is $24.8 k.
Who are Aptinyx competitors?
Competitors of Aptinyx include XBiotech, Bicycle Therapeutics and Rubius Therapeutics.
Where is Aptinyx headquarters?
Aptinyx headquarters is located at 909 Davis St #600, Evanston.
Where are Aptinyx offices?
Aptinyx has an office in Evanston.
How many offices does Aptinyx have?
Aptinyx has 2 offices.
Receive alerts for 300+ data fields across thousands of companies